Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRESON-01: rhTSH (SNA001) vs thyroid hormone withdrawal for postoperative radioiodine ablation in differentiated thyroid cancer
ChiCTR2100046907Phase 3Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SNA001 in well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Remnant ablative rate. Started Feb 2020; status: completed.
02
Drugs
SNA001
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2100046907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046907.